Novel methods of engineering
therapeutic exosomes
Innovation
Our proprietary engineering platform allows us to develop a new class of exosome-based therapeutics.
Speed
Entelexo rapidly prototypes therapeutics with applications in a variety of autoimmune diseases.
Risk Mitigation
We have built an initial pipeline of products, and we have de-risked these drug candidates using human cell assays.
Exosomes
Are nature’s cell to cell communication system, delivering messages that different cells can understand using receptors on their surface.
Entelexo
Built a platform to hijack the communication network using exosomes engineered to deliver messages to multiple, specific cell types simultaneously. We are leveraging this unique technology for modern treatments of autoimmune diseases – conditions that remain uncured due to their complexity.
Our Science / Tech
Until today
Autoimmune diseases such as Rheumatoid Arthritis, Crohn’s Disease, and Psoriasis affect millions of patients and have no cure. Existing treatments are formulated as a ‘one size fits all’ and block a single cytokine (such as TNF-ɑ). This approach does not address the true complexities associated with autoimmune diseases, which involve several cell types and pathways.
Until today
Autoimmune diseases such as Rheumatoid Arthritis, Crohn’s Disease, and Psoriasis affect millions of patients and have no cure. Existing treatments are formulated as a ‘one size fits all’ and block a single cytokine (such as TNF-ɑ). This approach does not address the true complexities associated with autoimmune diseases, which involve several cell types and pathways.
Starting today
Entelexo offers a new approach to treating autoimmune diseases by focusing on the patients, analyzing patterns, and utilizing data to optimize product efficacy.
Our engineered exosomes communicate with multiple, specific types of diseased cells simultaneously. This represents the logical step forward in treatment strategy, where for the first time, the scope of novel treatments are capable of matching the natural complexities of autoimmune diseases. Our rational engineering platform enables us to rapidly create and fine tune indication-specific exosome treatments.
Starting today
Entelexo offers a new approach to treating autoimmune diseases by focusing on the patients, analyzing patterns, and utilizing data to optimize product efficacy.
Our engineered exosomes communicate with multiple, specific types of diseased cells simultaneously. This represents the logical step forward in treatment strategy, where for the first time, the scope of novel treatments are capable of matching the natural complexities of autoimmune diseases. Our rational engineering platform enables us to rapidly create and fine tune indication-specific exosome treatments.
Entelexo's Pipeline
Traction
2020
Founding of Entelexo
Lab operational
Filing of multiple patents
YC acceptance.
2021
YC Graduation
Completed Pre-Seed Raise
Scientific Advisory Board Formation
EFL acceptance
Candidate development/POC testing.
2022
Pre-IND animal studies staged
EFL Graduation
Start of patent prosecution
Winner of Pitch.Launch.Grow. Biotech Competition
Drug candidate Development completed
Drug Efficacy evaluated by Human Cell Immunoassays
Lead Drug Candidates selected.
2023
Presenting at JP Morgan biotech showcase
IND-enabling animal studies begin
Preparations begin to file for Pre-IND with FDA.
ⓒ 2022 Entelexo, Inc